CSIMarket
 
Cue Biopharma Inc   (CUE)
Other Ticker:  
 
 
Price: $1.9900 $-0.08 -3.865%
Day's High: $2.075 Week Perf: 12.43 %
Day's Low: $ 1.98 30 Day Perf: -15.32 %
Volume (M): 170 52 Wk High: $ 5.12
Volume (M$): $ 338 52 Wk Avg: $3.03
Open: $2.07 52 Wk Low: $1.70



 Market Capitalization (Millions $) 92
 Shares Outstanding (Millions) 46
 Employees 50
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -52
 Cash Flow (TTM) (Millions $) 25
 Capital Exp. (TTM) (Millions $) 0

Cue Biopharma Inc
Cue Biopharma Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, United States. The company is known for its innovative platform technology, called CUE (Control of Unity for Engineered T-Cells), which is designed to harness the body's immune system to fight cancer and other diseases. Cue Biopharma is focused on developing and commercializing therapies that can selectively and specifically target disease-causing cells or tissues, while sparing healthy cells.

The company's primary technology is based on an engineered immune system called Immuno-STATs. Immuno-STATs are a type of molecule that is designed to selectively target and engage immune cells to attack specific disease-causing cells or tissues. This approach has the potential to overcome some of the limitations of traditional immune-based therapies, such as autoimmune reactions in healthy tissue, low response rates, or reduced efficacy over time.

Cue Biopharma's lead product candidate, CUE-101, is a therapeutic, single-chain T cell receptor (sTCR) targeting HPV+ cancers that is being developed for the treatment of head and neck cancer. The company has also developed several other Immuno-STATs, including CUE-102, CUE-103, and CUE-104, which are designed to target other types of cancers, such as melanoma and prostate cancer.

Cue Biopharma's Immuno-STAT platform technology has been validated in several preclinical studies and trials in animals, and the company has received funding and support from several government agencies, including the NIH, the NCI, and the DOD. The company has also entered into collaborations with several leading academic and clinical institutions, including the University of Texas MD Anderson Cancer Center, the Broad Institute of MIT and Harvard, and the Macromoltek Institute.

Cue Biopharma has a highly experienced management team, including President and CEO Daniel Passeri and Chief Medical Officer Ken Pienta, both of whom bring extensive experience in the biopharmaceutical industry. The company is committed to maintaining high ethical standards in all of its operations and has implemented a comprehensive compliance program to ensure that its research and development activities are conducted in accordance with industry best practices and regulatory requirements.

In conclusion, Cue Biopharma is a highly innovative biopharmaceutical company with a strong focus on developing and commercializing therapies that can selectively and specifically target disease-causing cells or tissues, while sparing healthy cells. The company's Immuno-STAT platform technology has the potential to transform the treatment of cancer and other diseases, and its experienced management team and commitment to ethical practices make it a leading player in the biopharmaceutical industry.


   Company Address: 40 Guest Street Boston 2135 MA
   Company Phone Number: 949-2680   Stock Exchange / Ticker: NASDAQ CUE
   CUE is expected to report next financial results on March 20, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Cue Biopharma's Innovative Therapy, CUE-101, Highlighted at Leading Head and Neck Cancers Symposium

Published Thu, Feb 29 2024 3:00 PM UTC

Cue Biopharma, Inc. (Nasdaq: CUE), a pioneering clinical-stage biopharmaceutical company focused on the development of disease-specific T-cell modulating therapeutic biologics, is proud to announce that their lead clinical asset, CUE-101, will be featured at the prestigious 2024 Multi-disciplinary Head and Neck Cancers Symposium. The symposium will showcase a presentation by...

Cue Biopharma Inc

Cue Biopharma Inc. Achieves Remarkable Q3 2023 Earnings Season, Delivering Blowout Results

Cue Biopharma Inc: A Bearish Outlook for Investors
Cue Biopharma Inc, a Major Pharmaceutical Preparations company, recently reported its financial results for the interval closing September 30, 2023. Despite certain improvements and a surge in revenue, there are several indicators that suggest potential challenges ahead for the company. This article will delve into the financial data and market trends to paint a bearish picture for Cue Biopharma Inc.
Firstly, let's analyze Cue Biopharma Inc's earnings per share (EPS) performance. Although the company managed to decrease its loss from $-0.31 per share to $-0.24 per share compared to the previous year, it is concerning that the company continues to operate at a loss. This raises questions about the company's ability to generate sustainable profits in the future.

Cue Biopharma Inc

Cue Biopharma Inc Reports Revenue Surge in Q2 2023, but Faces $0.29 Per Share Shortfall



Cue Biopharma Inc recently reported a significant revenue improvement in the second quarter of 2023. Despite this positive development, the company's financials suggest a concerning trend. This article aims to analyze Cue Biopharma's financial performance and highlight potential risks, including their earnings report, accounts receivable build-up, and market performance.
Revenue Growth Correlation:
Cue Biopharma witnessed a remarkable revenue growth of 5215.385% year-on-year, totaling $1.38 million in the second quarter of 2023. This growth seems impressive when compared to its peers in the Major Pharmaceutical Preparations sector, which recorded an average top-line improvement of 0.89% during the same period. However, caution must be exercised when analyzing such exponential growth, as it may be unsustainable or indicate a reliance on non-recurring events.

Cue Biopharma Inc

Cue Biopharma's Revenue Plummets by 81.3% in Q1 2023 Earnings Season

Cue Biopharma Inc, a company within the Healthcare sector, recorded a cumulative net loss of $-52 million during 12 months ending in the first quarter of 2023, resulting in a negative return on assets (ROA) of -62.11%. While this may seem concerning, it is important to note that 369 other companies within the same sector had a higher return on assets. The overall ranking for ROA has also improved for Cue Biopharma Inc, moving up to 2306 from 4744 in the previous quarter.
Despite the negative ROA, Cue Biopharma Inc has made progress in reducing their losses. In the most recent fiscal period, they decreased their loss per share from $-0.44 to $-0.29 compared to the previous year. Additionally, their EPS improved from $-0.34 in the preceding quarter. Although revenue dropped by -81.3% to $0.19 million from $1.00 million in the same quarter a year ago, there was a sequential improvement of 23.655% from $0.15 million. In the most recent quarter, the net shortfall was $-13.109 million, an improvement from the deficit of $-14.255 million in the same quarter a year ago.






 

Cue Biopharma Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com